Proposed ISTH hemophilia treatment guidelines risk damaging access to products for patients worldwide
In October, 2023, the International Society on Thrombosis and Haemostasis (ISTH) issued draft guidelines on the treatment of hemophilia for community comment. These guidelines consist of 13 rated recommendations that pertain to the treatment of hemophilia A and B, such as the choice between prophylaxis and episodic treatment, preference for a treatment modality (plasma-derived, standard or extended half-life recombinant factors, bispecific antibody), or use of bypassing agents in patients with an inhibitor. More than 400 comments regarding these 13 statements were received and evaluated by ISTH. However, the ISTH indicated in advance that the wording of each recommendation would not change. The final guidelines are expected to be published in May, 2024.